Document Detail


Efficacy and safety of the topical sensitizer squaric acid dibutyl ester in Alopecia areata and factors influencing the outcome.
MedLine Citation:
PMID:  16573260     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Immunotherapy with sqauric acid dibutyl ester (SADBE) is a well-accepted therapy for alopecia areata. OBJECTIVE: To study efficacy, safety, and factors influencing the outcome in the treatment of alopecia areata. METHOD: During a 4-year period, 70 patients of alopecia areata, unresponsive to conventional therapies, were treated with SADBE for a period of 4 months and thereafter depending on the response with initial therapy. The percent scalp hair loss was calculated using "Severity of Alopecia Tool" (SALT) score before and after the therapy. RESULTS: Out of 70 patients, 6 were lost to follow-up and 4 could not develop sensitization; therefore, data of 60 patients was available for analysis. The overall success rate was 43%. In patients with <50% scalp involvement; the success rate was better (68%) than in those with >50% involvement (29%). The response was better in patients with late onset and shorter duration of disease. Family history of alopecia areata or other autoimmune diseases, personal or family history of atopy, presence of auto antibodies in serum, and presence of nail changes were associated with poorer prognosis. Out of 26 patients who responded, relapse occurred in 21 (81%) patients. CONCLUSION: In conclusion, SADBE is an effective and well-tolerated mode of therapy in Indian patients of AA, although the long-term results of SADBE were not encouraging.
Authors:
C Ajith; Somesh Gupta; Amrinder Jit Kanwar
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Journal of drugs in dermatology : JDD     Volume:  5     ISSN:  1545-9616     ISO Abbreviation:  J Drugs Dermatol     Publication Date:  2006 Mar 
Date Detail:
Created Date:  2006-03-31     Completed Date:  2006-06-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160020     Medline TA:  J Drugs Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  262-6     Citation Subset:  IM    
Affiliation:
Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adjuvants, Immunologic / administration & dosage*,  adverse effects
Administration, Cutaneous
Adolescent
Adult
Alopecia Areata / drug therapy*,  pathology
Child
Cyclobutanes / administration & dosage*,  adverse effects
Female
Humans
India
Male
Middle Aged
Severity of Illness Index
Treatment Outcome
Chemical
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Cyclobutanes; 2892-62-8/squaric acid dibutyl ester

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a ...
Next Document:  Gel vehicles are not inherently more irritating than creams.